

QMIIZ (meloxicam, oral-disintegrating tablet)

Diagnoses Considered for Coverage:

- Osteoarthritis pain

Coverage Criteria:

For diagnosis above:

- Intolerable side effect to meloxicam tablet (Mobic) not expected with Qmiiz, and
- Dose does not exceed FDA label maximum.

Coverage Duration: one year

Effective Date: 09/27/2023